Dorian Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana
FDA Grants Humanitarian Use Device Designation to Bionaut Labs for Treatment of Dandy Walker Syndrome
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Can biotech change its DNA? Racial equity remains a missing ingredient in the industry
bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Message :
Required fields
Shanghai Stock Exchange listed company HitGen Inc. (“HitGen”) today announced that it has entered into a research collaboration agreement with Dorian Therapeutics, Inc. (“Dorian”), a private biotechnology company developing senoblockers, a new class of therapeutics that can rejuvenate cells and tissues. HitGen will apply its platform technology, based on the design, synthesis and screening of DNA-encoded libraries (DEL) to discover compounds that bind to certain targets that are of interest to Dorian. Under the terms of the agreement, HitGen will receive an undisclosed upfront payment and will be eligible for milestone payments from Dorian.
HitGen is a world leader in the development of the DEL technology and applications to early-stage small molecule drug discovery. The availability of over 1 trillion small molecules generated by the DEL technology and the efficiency of the screening process have made it possible for HitGen to enable drug discove